The osteo-anabolic effect of estrogen administration requires DNA-binding of ERα in osteoblasts.

<p>Von Kossa/van Gieson-staining of non-decalcified spine <b>A)</b> and tibia <b>B)</b> sections of <i>ERα^fl/fl</i> mice carrying the <i>LysM-Cre</i> or the <i>Runx2-Cre</i> transgene, receiving the same treatment. <b>C)</b> Quantification of BV/TV in ERα^LysMCre and ERα^Runx2Cre mice receiving no treatment or estrogen treatment. Von Kossa/van Gieson-staining of non-decalcified spine <b>D)</b> and tibia <b>E)</b> sections of ERa^EAAE mice receiving no (−E2) or estrogen (+E2) treatment. <b>F)</b> Quantification of BV/TV in ERa^EAAE mice receiving no treatment or estrogen treatment. All data represent mean ± SD from at least 4 mice per group. ^#p<0.05 versus control under basal conditions; *p<0.05 versus control following estrogen treatment.